Limits...
Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in the State of Qatar.

Al-Dewik NI, Jewell AP, Yassin MA, Morsi HM - Biomark Cancer (2015)

Bottom Line: There was no significant difference or correlation between AGP levels and the different groups of patients.There was also no significant difference in the fluorescence intensities of PGP levels among the different patient groups.There was no significant pattern of AGP and PGP expression, irrespective of the response or resistance to treatment.

View Article: PubMed Central - PubMed

Affiliation: National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar. ; Qatar Medical Genetics Center, Hamad Medical Corporation (HMC), Doha, Qatar. ; Faculty of Health and Social Care Sciences, Kingston University and St George's University of London, UK.

ABSTRACT
Despite the efficacy of imatinib mesylate (IM) in treating chronic myeloid leukemia (CML), there is a high degree of resistance. Alpha- 1-acid glycoprotein may reduce drug efficacy through its ability to interact with IM and blocks it from reaching its target, while protein glycoprotein (PGP) may reduce the intracellular concentration of the drug via an active pump mechanism. We thus investigated the correlation between AGP and PGP levels and the resistance/response to treatment. A total of 26 CML patients were investigated for AGP and PGP levels at diagnosis and during treatment. There was no significant difference or correlation between AGP levels and the different groups of patients. There was also no significant difference in the fluorescence intensities of PGP levels among the different patient groups. The resistance observed in our CML patient population could not be correlated with AGP and PGP levels. There was no significant pattern of AGP and PGP expression, irrespective of the response or resistance to treatment.

No MeSH data available.


Related in: MedlinePlus

Mean results of PGP/control ratio of different CML groups.Notes: The mean PGP expression levels were 1.25 (±0.06), 1.17 (±0.02), 1.21 (±0.03), and 1.2 (±0.04) for AP, CP, optimal responders, and resistant groups, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4664201&req=5

f2-bic-7-2015-063: Mean results of PGP/control ratio of different CML groups.Notes: The mean PGP expression levels were 1.25 (±0.06), 1.17 (±0.02), 1.21 (±0.03), and 1.2 (±0.04) for AP, CP, optimal responders, and resistant groups, respectively.

Mentions: The mean PGP levels were 1.25 (±0.06), 1.17 (±0.02), 1.21 (±0.03), and 1.2 (±0.04) g/L for AP, CP, optimal responders, and resistant group, respectively. Flow cytometric analysis showed no significant difference in the fluorescence intensities of blast cells incubated with CD243 and blast cells incubated with isotypic control among the different diseased groups. (Figs. 2 and 3).


Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in the State of Qatar.

Al-Dewik NI, Jewell AP, Yassin MA, Morsi HM - Biomark Cancer (2015)

Mean results of PGP/control ratio of different CML groups.Notes: The mean PGP expression levels were 1.25 (±0.06), 1.17 (±0.02), 1.21 (±0.03), and 1.2 (±0.04) for AP, CP, optimal responders, and resistant groups, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4664201&req=5

f2-bic-7-2015-063: Mean results of PGP/control ratio of different CML groups.Notes: The mean PGP expression levels were 1.25 (±0.06), 1.17 (±0.02), 1.21 (±0.03), and 1.2 (±0.04) for AP, CP, optimal responders, and resistant groups, respectively.
Mentions: The mean PGP levels were 1.25 (±0.06), 1.17 (±0.02), 1.21 (±0.03), and 1.2 (±0.04) g/L for AP, CP, optimal responders, and resistant group, respectively. Flow cytometric analysis showed no significant difference in the fluorescence intensities of blast cells incubated with CD243 and blast cells incubated with isotypic control among the different diseased groups. (Figs. 2 and 3).

Bottom Line: There was no significant difference or correlation between AGP levels and the different groups of patients.There was also no significant difference in the fluorescence intensities of PGP levels among the different patient groups.There was no significant pattern of AGP and PGP expression, irrespective of the response or resistance to treatment.

View Article: PubMed Central - PubMed

Affiliation: National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar. ; Qatar Medical Genetics Center, Hamad Medical Corporation (HMC), Doha, Qatar. ; Faculty of Health and Social Care Sciences, Kingston University and St George's University of London, UK.

ABSTRACT
Despite the efficacy of imatinib mesylate (IM) in treating chronic myeloid leukemia (CML), there is a high degree of resistance. Alpha- 1-acid glycoprotein may reduce drug efficacy through its ability to interact with IM and blocks it from reaching its target, while protein glycoprotein (PGP) may reduce the intracellular concentration of the drug via an active pump mechanism. We thus investigated the correlation between AGP and PGP levels and the resistance/response to treatment. A total of 26 CML patients were investigated for AGP and PGP levels at diagnosis and during treatment. There was no significant difference or correlation between AGP levels and the different groups of patients. There was also no significant difference in the fluorescence intensities of PGP levels among the different patient groups. The resistance observed in our CML patient population could not be correlated with AGP and PGP levels. There was no significant pattern of AGP and PGP expression, irrespective of the response or resistance to treatment.

No MeSH data available.


Related in: MedlinePlus